Sumy C. Daeufer

PRINCIPAL

781 795 4706 direct

sumy.daeufer@faberlawgroup.com

Industry Experience

Associate General Counsel and Development Group
Millennium Pharmaceuticals, Inc. (now Takeda Pharmaceutical Company Limited)

Counsel to Parke-Davis pharmaceutical division
Warner-Lambert Company (now Pfizer)

Sumy's background in the life sciences make her particularly adept at guiding clients through complex transactions that drive value in all phases of drug development from R&D to commercial product licensing. As lead transactional counsel she helps clients navigate and negotiate strategic product research, development and commercialization transactions, technology and product licensing, academic research collaborations and licensing and commercial product manufacturing and supply chain transactions. Sumy also supervises Faber's contract support team for large international clinical trials.

EXPERIENCE

Millennium Pharmaceuticals, Inc. (now **Takeda Pharmaceutical Company, Limited**)

Associate General Counsel and Development Group

- Manager of the Discovery and Development Group within the legal department
- Member of the committee responsible for managing Millennium's product pipeline
- Business team member for the company's marketed products
- Lead in-house attorney for the development and commercialization alliance for Millennium's first oncology drug

Warner-Lambert Company (now **Pfizer**)

Counsel to Parke-Davis Pharmaceutical Division in North America and South Africa

Sidley Austin LLP
Business Transactions Group

- Focused on secured financing, M&A transactions, and initial public offerings

Bar Admissions

- Massachusetts
- New York

Education

- Yale Law School, J.D.
- Yale University, B.A., *summa cum laude*

RECENT CLIENT WORK

- Alnylam's research and development collaboration with Vir Biotechnology to develop RNAi therapeutics for chronic hepatitis B virus and other infectious diseases
- ImmunoGen's sale and license to Debiopharm of its Phase 2 anti-CD37 non-Hodgkin lymphoma (NHL) antibody-drug conjugate (ADC) product program
- AB Biosciences' exclusive license to Shire of its recombinant immunoglobulin product
- EpimAb's research and development collaboration with Kymab for bispecific therapeutic antibodies
- Biogen's research collaboration with Arsia Therapeutics to develop subcutaneous formulations of Biogen's hemophilia products
- Alnylam's expansion of its strategic alliance and broad crosslicensing arrangement with Isis Pharmaceuticals (now Ionis Pharmaceuticals)
- Biogen's drug discovery collaboration with Array BioPharma for kinase inhibitors for inflammatory disease
- Atara Biotherapeutics' exclusive license of clinical-stage T-cell therapy technology from Memorial Sloan Kettering Cancer Center
- Biogen's in-license and transfer of an antibody discovery technology platform from Adimab
- Alnylam's license and collaboration agreement with The Medicines Company for siRNA molecules targeting PCSK9
- Biogen's drug discovery collaboration with Amicus in Parkinson's
- Alnylam's exclusive global alliance with the The Medicines Company for the development and commercialization of Alnylam's ALN-PCS RNAi therapeutic program for hypercholesterolemia
- Alnylam's strategic collaboration with Ascletis to develop an RNAi therapeutic for liver cancer in China
- Phenex's research collaboration and license agreement with Janssen for autoimmune and chronic inflammatory disorders
- Alnylam's strategic alliance with Monsanto in the field of agriculture
- Arsanis' discovery collaboration agreement with Adimab
- Alnylam's exclusive alliance with Kyowa Hakko Kogyo to develop and commercialize ALN-RSV01, a clinical stage RNAi therapeutic for the treatment of respiratory syncytial virus (RSV) infection, in Japan and other major markets in Asia
- Alnylam's strategic delivery technology collaborations with Inex, Protiva and Tekmira (now collectively, Arbutus)